JP5020463B2 - ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 - Google Patents

ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 Download PDF

Info

Publication number
JP5020463B2
JP5020463B2 JP2004212054A JP2004212054A JP5020463B2 JP 5020463 B2 JP5020463 B2 JP 5020463B2 JP 2004212054 A JP2004212054 A JP 2004212054A JP 2004212054 A JP2004212054 A JP 2004212054A JP 5020463 B2 JP5020463 B2 JP 5020463B2
Authority
JP
Japan
Prior art keywords
riera
dunaliella
donna
genus
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004212054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005097255A (ja
JP2005097255A5 (enExample
Inventor
アビブ・シヤイシユ
ドロル・ハラツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikken Sohonsha Corp
Original Assignee
Nikken Sohonsha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Sohonsha Corp filed Critical Nikken Sohonsha Corp
Publication of JP2005097255A publication Critical patent/JP2005097255A/ja
Publication of JP2005097255A5 publication Critical patent/JP2005097255A5/ja
Application granted granted Critical
Publication of JP5020463B2 publication Critical patent/JP5020463B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004212054A 2003-09-24 2004-07-20 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 Expired - Fee Related JP5020463B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/668,601 US7264813B2 (en) 2003-09-24 2003-09-24 Therapeutic uses of Dunaliella powder
US10/668601 2003-09-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009187809A Division JP5356946B2 (ja) 2003-09-24 2009-08-13 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用

Publications (3)

Publication Number Publication Date
JP2005097255A JP2005097255A (ja) 2005-04-14
JP2005097255A5 JP2005097255A5 (enExample) 2005-09-29
JP5020463B2 true JP5020463B2 (ja) 2012-09-05

Family

ID=34313520

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2004212054A Expired - Fee Related JP5020463B2 (ja) 2003-09-24 2004-07-20 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2009187809A Expired - Lifetime JP5356946B2 (ja) 2003-09-24 2009-08-13 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2013126599A Withdrawn JP2013177457A (ja) 2003-09-24 2013-06-17 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2016104166A Expired - Fee Related JP6321074B2 (ja) 2003-09-24 2016-05-25 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2017235555A Expired - Lifetime JP6490782B2 (ja) 2003-09-24 2017-12-07 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009187809A Expired - Lifetime JP5356946B2 (ja) 2003-09-24 2009-08-13 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2013126599A Withdrawn JP2013177457A (ja) 2003-09-24 2013-06-17 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2016104166A Expired - Fee Related JP6321074B2 (ja) 2003-09-24 2016-05-25 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2017235555A Expired - Lifetime JP6490782B2 (ja) 2003-09-24 2017-12-07 ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用

Country Status (5)

Country Link
US (3) US7264813B2 (enExample)
EP (2) EP1522310B1 (enExample)
JP (5) JP5020463B2 (enExample)
AT (1) ATE548046T1 (enExample)
IL (1) IL162987A (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210917A (ja) * 2006-02-08 2007-08-23 Kochi Univ 脂肪細胞縮小化剤、医薬品及び飲食品
WO2007109824A1 (en) * 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
JP2008222555A (ja) * 2007-03-08 2008-09-25 Nagasakiken Koritsu Daigaku Hojin アディポネクチン受容体発現増加剤
WO2009105048A2 (fr) * 2008-02-19 2009-08-27 Rached Smida Nouvelles applications du hdl reconstitué
EP2296682B8 (en) 2008-04-29 2018-07-04 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
US20100303989A1 (en) 2008-10-14 2010-12-02 Solazyme, Inc. Microalgal Flour
JP5733592B2 (ja) * 2008-10-20 2015-06-10 株式会社日健総本社 脂質異常治療薬の副作用防止物質
WO2010102056A1 (en) * 2009-03-03 2010-09-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
US9180152B2 (en) 2009-12-10 2015-11-10 Nikken Sohonsha Corporation Method for treating psoriasis
JP5736394B2 (ja) 2010-03-02 2015-06-17 ヴィシェイ−シリコニックス 半導体装置の構造及びその製造方法
US10098371B2 (en) 2013-01-28 2018-10-16 Solazyme Roquette Nutritionals, LLC Microalgal flour
FR3009619B1 (fr) 2013-08-07 2017-12-29 Roquette Freres Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee
GB201718822D0 (en) 2017-11-14 2017-12-27 Univ Greenwich Production of dunaliella
JP6947665B2 (ja) * 2018-03-13 2021-10-13 アイカ工業株式会社 光硬化性粘着樹脂組成物
US20220175860A1 (en) * 2019-04-01 2022-06-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Dunaliella alga preparation for prevention and/or treatment of a neurodegenerative disease, a disorder associated with protein misfolding and cognitive decline

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199895A (en) 1977-05-25 1980-04-29 Yeda Research And Development Co. Ltd. Production of glycerol, carotenes and algae meal
USPP4511P (en) 1978-06-26 1980-03-18 Yeda Research & Development Co. Ltd. Alga strain
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
IL87260A (en) * 1988-02-25 1991-12-15 Tanaka Yoshio Encapsulated food containing dunaliella algae and its production
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5219888A (en) 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
WO1993024454A1 (en) 1992-06-04 1993-12-09 Betatene Limited High cis beta-carotene composition
US6262109B1 (en) * 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
WO1997010819A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
EP0788353A1 (en) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
IL119224A (en) 1996-09-09 2002-11-10 Hadasit Med Res Service Medicament for protection from effects of irradiation
JP3037628B2 (ja) * 1997-03-06 2000-04-24 マイクロアルジェコーポレーション株式会社 健康補助食品用軟カプセルの製法
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
EP1144997A3 (en) 1998-03-30 2002-08-28 The Regents of the University of California Methods and compounds for modulating nuclear receptor activity
DE69929996T2 (de) 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2002333655A1 (en) 2001-09-25 2003-04-07 Smithkline Beecham Corporation Bicyclic heterocycles as rxr ligands
IN189624B (enExample) * 2001-10-23 2003-03-29 Ajanta Pharma Ltd
JP3978582B2 (ja) * 2001-12-19 2007-09-19 株式会社日健総本社 カロチノイドの製造方法
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Also Published As

Publication number Publication date
EP1522310B1 (en) 2012-03-07
EP2269620A1 (en) 2011-01-05
US20080019997A1 (en) 2008-01-24
US7264813B2 (en) 2007-09-04
JP6490782B2 (ja) 2019-03-27
US20100221348A1 (en) 2010-09-02
JP2005097255A (ja) 2005-04-14
US7763255B2 (en) 2010-07-27
JP2016147916A (ja) 2016-08-18
JP5356946B2 (ja) 2013-12-04
US20050063991A1 (en) 2005-03-24
JP2018035200A (ja) 2018-03-08
JP2013177457A (ja) 2013-09-09
IL162987A (en) 2013-06-27
EP1522310A1 (en) 2005-04-13
JP6321074B2 (ja) 2018-05-09
HK1071845A1 (en) 2005-08-05
US8343549B2 (en) 2013-01-01
ATE548046T1 (de) 2012-03-15
JP2009256392A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
JP5356946B2 (ja) ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用
JP2009256392A5 (enExample)
CN1993119B (zh) 含他汀类药物和ω-3脂肪酸的组合物
JP2755559B2 (ja) 前脂肪細胞の分化を刺激する組成物と方法、およびこれに関連する治療処置方法
AU2001286576B2 (en) Composition and method for treatment of hypertriglyceridemia
EA011637B1 (ru) Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт
AU2001286576A1 (en) Composition and method for treatment of hypertriglyceridemia
AU2015279905A1 (en) Treatment of severe hypertriglyceridemia
JPS6299323A (ja) 高脂血症剤
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
HK1071845B (en) Therapeutic uses of dunaliella powder
JP2020503388A (ja) 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物
WO1993009773A1 (fr) Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee
JPWO2000035867A1 (ja) 核内受容体の新規リガンド
HK1105871B (en) Composition containing statins and omega-3 fatty acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050720

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100217

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120613

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5020463

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150622

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees